In its earnings call, John Martin, chairman and CEO, and soon to be executive chairman, of biopharmaceutical company heavyweight Gilead Sciences Inc., described 2015 as an "exceptional year" for the company, which experienced progress on a number of therapeutic fronts including HIV and hepatitis. The Foster City, Calif.-based company reported an increase in total revenues for both the fourth quarter of 2015 and full year beating Wall Street estimates.